On June 5, 2026, the FDA cleared EyeBOX SNAP from Oculogica, Inc. through the 510(k) pathway, recording it as clearance number K254086, a Traditional submission found Substantially Equivalent. The device was received for review on December 18, 2025 and sits in the Neurology advisory panel under product code QEA and regulation 882.1455, a Class II device.
EyeBOX is an eye-tracking system that records a patient's oculomotor responses — how the eyes move — and produces an interpretation tied to brain function. The category is one of the more carefully fenced corners of consumer-adjacent neurotech, because the public appetite for a quick, objective concussion check runs well ahead of what the regulatory record actually permits any device to claim. The FDA's classification language for QEA is unusually explicit about that boundary.
"A traumatic brain injury eye movement assessment aid is a prescription device that uses a patients tracked eye movements to provide an interpretation of the functional condition of the patients brain. This device is an assessment aid that is not intended for standalone detection or diagnostic purposes."— FDA Product Classification, product code QEA, source
Two words in that definition do almost all the work: prescription and aid. EyeBOX SNAP is not an over-the-counter consumer gadget, and it is not a device that detects or diagnoses traumatic brain injury on its own. It is an adjunctive interpretive assessment aid — a tool that a clinician layers on top of clinical judgment, not a replacement for it.
Why the scope language is the headline
For anyone reading this through a consumer or sports-tech lens, the temptation is to frame an eye-tracking brain-injury device as the long-promised sideline concussion test. The FDA's own words foreclose that framing. The classification states the device 'is not intended for standalone detection or diagnostic purposes.' That single sentence governs what Oculogica can lawfully claim, what marketing language the clearance supports, and how the device fits into a clinical workflow.
This is the recurring lesson of the neuro-assessment category. A 510(k) clearance describes substantial equivalence to a predicate within a tightly drawn product code; it does not expand the device's intended use beyond the regulation that defines QEA. The 'SNAP' designation in the device name suggests a faster or more portable iteration of Oculogica's prior EyeBOX work, but a more convenient form factor does not loosen the scope. The interpretive output remains an aid, and the device remains prescription-only.
The technology, framed precisely
Oculomotor assessment rests on a defensible premise: the neural circuitry that controls eye movement is distributed across brain regions vulnerable to injury, so quantifying disconjugate or abnormal eye motion can yield an objective signal correlated with functional status. That is genuinely useful. But there is a difference between a correlated functional signal and a diagnosis, and the QEA regulation is built around exactly that difference. The device interprets 'the functional condition of the patients brain' — a measured functional state — rather than rendering a yes/no injury verdict.
For R&D strategists watching the neurotech landscape, the takeaway is about where the regulatory white space actually sits. Standalone, OTC concussion diagnosis is not a cleared category here; adjunctive interpretive aids are. Companies building eye-tracking, EEG, or pupillometry products into this space inherit the same fence Oculogica operates within. The path to broader claims runs through harder evidence and a different regulatory posture than a Traditional 510(k) in the QEA code can support.
Reading the clearance like a practitioner
A useful way to internalize what K254086 does and does not authorize is to separate three layers that casual coverage tends to collapse. The first layer is the device identity: EyeBOX SNAP is a specific product from a specific applicant, Oculogica, cleared on a specific date. The second is the regulatory category: product code QEA, regulation 882.1455, Class II, Neurology panel. The third is the scope language: the function statement that governs intended use. Marketing operates almost entirely at the first layer; clinical and legal reality operate at the second and third. When a headline says a device 'detects concussions,' it has quietly jumped from the third layer to a claim the third layer does not support.
The QEA definition is built to prevent exactly that jump. It establishes the device as prescription-only, which channels it through a clinician, and it labels the output an interpretation of 'the functional condition of the patients brain' rather than a determination of injury. The word 'adjunctive' in the product code's full title — 'Brain Injury Adjunctive Interpretive Oculomotor Assessment Aid' — is the load-bearing modifier. Adjunctive means alongside; the device supplements an evaluation, it does not constitute one. For an IP or regulatory strategist, that modifier is the difference between a clearable Class II aid and a far harder-to-clear standalone diagnostic.
There is also a competitive dimension. Because the category is defined as an aid rather than a diagnostic, multiple vendors can occupy it without any one of them being able to claim the decisive 'objective concussion test' positioning that the public wants and the market would reward. That keeps the category crowded with assistive tools and the genuinely differentiated, diagnosis-grade claim perpetually just out of reach — gated behind evidence and a regulatory posture that a Traditional 510(k) in QEA does not deliver.
What the record establishes — and what it does not
The openFDA entry establishes, verbatim and without inference, that EyeBOX SNAP is Oculogica's device, that it cleared on June 5, 2026 as K254086, that the determination was Substantially Equivalent, and that it is classified as a Class II Neurology device under product code QEA. The classification record supplies the scope language quoted above. What the entry does not tell us is the named predicate, the specific oculomotor metrics, or the population in which performance was demonstrated — those live in the full 510(k) summary.
Still, the most important fact about this clearance is the one the FDA states plainly and the one a casual reader is most likely to miss: EyeBOX SNAP is an aid, prescribed and adjunctive, and not a standalone test. In a category where the marketing gravity always pulls toward 'objective concussion detection,' the regulatory record pulls firmly back. Scope ends where the classification ends, and here the classification is clear.